Page last updated: 2024-11-03

probenecid and Lupus Erythematosus, Systemic

probenecid has been researched along with Lupus Erythematosus, Systemic in 1 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Helliwell, M1
Crisp, AJ1
Grahame, R1

Other Studies

1 other study available for probenecid and Lupus Erythematosus, Systemic

ArticleYear
Co-existent tophaceous gout and systemic lupus erythematosus.
    Rheumatology and rehabilitation, 1982, Volume: 21, Issue:3

    Topics: Adult; Allopurinol; Gout; Humans; Lupus Erythematosus, Systemic; Male; Probenecid

1982